Stock Watch: Fewer Acquisitions Leave Many Behind
For Every Biotech Buyout There Will Be Several Left At The Altar
The biotech sector is so diverse that for every acquisition there will be at least one second-best. Even after years of independence following a drug approval, investors keep hoping that their pharmaceutical Prince Charming will arrive.
